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Abstract
Chromosome 3p21–22 harbors two clusters of chemokine receptor genes, several of which serve as major or minor
coreceptors of HIV-1. Although the genetic association of CCR5 and CCR2 variants with HIV-1 pathogenesis is well known,
the role of variation in other nearby chemokine receptor genes remain unresolved. We genotyped exonic single nucleotide
polymorphisms (SNPs) in chemokine receptor genes: CCR3, CCRL2, and CXCR6 (at 3p21) and CCR8 and CX3CR1 (at 3p22), the
majority of which were non-synonymous. The individual SNPs were tested for their effects on disease progression and
outcomes in five treatment-naı ¨ve HIV-1/AIDS natural history cohorts. In addition to the known CCR5 and CCR2 associations,
significant associations were identified for CCR3, CCR8, and CCRL2 on progression to AIDS. A multivariate survival analysis
pointed to a previously undetected association of a non-conservative amino acid change F167Y in CCRL2 with AIDS
progression: 167F is associated with accelerated progression to AIDS (RH=1.90, P=0.002, corrected). Further analysis
indicated that CCRL2-167F was specifically associated with more rapid development of pneumocystis pneumonia (PCP)
(RH=2.84, 95% CI 1.28–6.31) among four major AIDS–defining conditions. Considering the newly defined role of CCRL2 in
lung dendritic cell trafficking, this atypical chemokine receptor may affect PCP through immune regulation and inducing
inflammation.
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Introduction
Functional variation in the human leukocyte antigen (HLA) class I
genes and in chemokine receptors affects HIV susceptibility, viral
load, and rates of disease progression [1–4]. Recent genome-wide
association studies(GWAS) performed in HIV-1 cohorts haveshown
that the HLA region and the chemokine receptor CCR5 gene have
majorrolesincontrolofHIV-1replicationanddiseaseprogression—
together they explain approximately 20% of genetic variability [3,5–
8] (reviewed in [4,5]). These findings from GWAS highlighted the
leadingroleofchemokinereceptorsamongnon-HLAgenesin HIV-1
pathogenesis and prompted us to assess the role of other chemokine
receptor genes on HIV disease using a gene-centric approach to
identify common or rare functional variants in the region.
The chemokine receptor cluster on chromosome 3 contains at
least 12 genes including CCR5, the primary HIV-1 co-receptor [9–
11]. Multiple genetic variants in chemokine receptors and
chemokines have been identified as modifiers of HIV-1 infection
or disease progression [12,13], including CCR5-D32 (a 32-bp
deletion introduces a premature stop codon) [14] and CCR5
promoter variants [15–17] and variants in the CCR5 ligand gene
CCL5 [18,19]. The homozygous CCR5 D32/D32 genotype and
complex heterozygotes with other rare amino acid mutations
confers near complete resistance to HIV infection [12,14,20–22].
Individuals homozygous for a haplotype known as CCR5-P1 [15]
or haplogroup HHE [23], a multisite allele of the CCR5 promoter
region, progress to AIDS more rapidly than those with other CCR5
promoter haplotypes [15–17,23–25]. CCR2 and CXCR6 are
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strains as an entry coreceptor [26,27]. CCR2-V64I has been
associated with delayed progression [12,25,28,29]. Variants in
CXCR6 were also associated with disease modification [30,31].
The chromosome 3 chemokine receptor cluster extends from
3p21 to 3p24, with eight receptors occurring in an 520 kb region
of 3p21(Figure 1) [32]. The cluster contains genes for several
receptors, CCR3, CCR8, CX3CR1, and CXCR6 that have been
shown to bind HIV env or to support varying levels of in vitro
replication of HIV-1, HIV-2 or simian immunodeficiency virus
(SIV) [26,33–36] (reviewed by [11,37]). The role played by minor
coreceptors in HIV-1 pathogenesis is not clear, but studies have
suggested that a broad spectrum of coreceptor usage may be
correlated with rapid CD4+ cell depletion and AIDS progression
[11,38,39]. Primary isolates of HIV-1 have been shown to use a
wide spectrum of various chemokine receptors as HIV corecep-
tors [40]. HIV-1 isolates from a CCR5-D32 heterozygous or
homozygous individual can use various minor coreceptors such as
CCR3, CCR2B, CCR8, CX3CR1 for cell entry [41,42]; amino
acid mutations in the V3 loop of HIV-1 are responsible for
utilization of multiple coreceptors [40]. Considering the high
mutation rate and sequence heterogeneity of HIV-1, particularly
within the env gene, it is plausible that a spectrum of receptors is
used in vivo during the course of HIV infection and that genetic
variants in the coreceptors may affect usage or binding efficiency
by HIV-1. Furthermore, as CCR5 and CXCR4 antagonists
blocking these major co-receptors are used therapeutically [37],
the potential of HIV-1 to evolve to use other minor coreceptors as
alternative cell entry points is expected to increase. Therefore,
determining whether HIV-1 minor coreceptor genes, in addition
to CCR5 and CXCR4 play a role in HIV pathogenesis is a timely
topic.
In this study, we evaluate the impact of chemokine coreceptors
(CCR) on HIV/AIDS using a candidate-gene based population
association analysis in five treatment-naive HIV-1 natural history
cohorts. Genotypes of exonic polymorphisms in chemokine coreceptor
genes CCR3, CCRL2 and CXCR6 on Chromosome 3p21 and in
CCR8 and CX3CR1 on 3p22 were tested for their genetic influence
on AIDS progression. CCR3, CCR8 and CXCR6 were chosen as
they are HIV-1 minor coreceptors [26,33–36] (reviewed by
[11,37]). CCRL2 was selected as a candidate gene because of its
homology with CCR5 (45%)—the most of any of the chemokine
receptors genes—because of its proximity to CCR5, and because it
is an atypical receptor without signal transduction, similar to
DARC. Our results suggest that genetic variation in CCR3, CCR8
and CCRL2 may contribute additional genetic regulation of HIV-1
disease in addition to that conferred by the major HIV-1
coreceptor gene CCR5.
Author Summary
Human chemokine receptors are cell surface proteins that
may be utilized by HIV-1 for entry into host cells. DNA
variation in the HIV-1 major coreceptor CCR5 affects HIV-1
infection and progression. This study comprehensively
assesses the role of genetic variation of multiple chemo-
kine receptor genes clustered in the chromosome 3p21
and 3p22 on HIV-1 disease outcomes in HIV-1 natural
history cohorts. The multivariate survival analyses identi-
fied functional variants that altered disease progression
rate in CCRL2, CCR3, and CCR8. CCRL2-F167Y affects the
rate to AIDS development through a specific protection
against pneumocystis pneumonia (PCP), a common AIDS–
defining condition. Our study identified this atypical
chemokine receptor CCRL2 as a key factor involved in
PCP, possibly through inducing inflammation in the lung.
Figure 1. Polymorphisms in seven chemokine receptor genes on the Chromosome 3p21–22. Schematics at bottom show the
configuration of the receptors in the cell membrane, with circles representing the position and type of the polymorphisms. White circle indicates a
synonymous substitution, colors nonsynonymous substitutions: yellow, conservative; blue, hydrophobic—hydrophilic; orange, hydrophilic—
hydrophobic; red, charge changing (acidic—basic), purple, shape changing. Also indicated are D32 in CCR5 (rectangle) and the polymorphic CCR5
promoter (red triangle in the gene map). CCR5-2459 promoter allele (rs1799987).
doi:10.1371/journal.pgen.1002328.g001
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Identification of chemokine coreceptor variants
We resequenced selected chemokine receptor genes in the
chromosome 3p21–22 region in 72 African Americans and 72
European Americans with three extreme phenotypes (resistance to
HIV infection, very rapid or slow progression to AIDS) to assess the
extent of exonic variation and to identify rare variants. We observed
a total of 6 exonic variants, 5 of which were nonsynonymous, in
CCR3, CCR8, CXCR6,a n dCCRL2 (Figure 1, Table 1). We did not
resequence CCR5 and CCR2 since these receptor genes had been
previously sequenced in HIV patients [28,43], nor did we
resequence CX3CR1. We previously showed that CX3CR1-V249I
and -T280M had no effect on AIDS progression in our group of
seroconverter subjects [44], and therefore did not include them in
this analysis. No noticeable differences in SNP frequency among
three extreme phenotype groups were observed (data not shown).
These SNPs were then genotyped in 5 HIV-1 natural cohorts
comprising 2594 European Americans (EA). All SNPs were in
Hardy-Weinberg Equilibrium (P.0.05). CXCR6-E3K and CCR3-
P39L were rare (,1%) in EA and were excluded from the analysis;
other SNPs were common (.5%) (Table 1).
Linkage disequilibrium (LD) of chemokine receptor
variants on 3p21–22
The SNPs considered fell into two distinct haplotype blocks
(Figure 1). The larger block in 3p21 comprises CCRL2-F167Y,
CCRL2-I243V, CCR5-+/D32, the CCR5-promoter SNP CCR5-
2459A (rs1799864, previously shown to affect CCR5 expression
levels and modify AIDS progression [15,16]), CCR2-V64I, CCR3-
P39L and CCR3-255T/C (Y17Y), spanning 77 Kb, and CXCR6-
E3K, 318 Kb teleomeric to CCR3. The second block in 3p22,
,10 Mb from the first block, consists of CX3CR1-V249I and -
T280M and CCR8-A27G (rs2853699), which are separated by
,160 Kb. There is moderate to substantial LD within the closely
spaced CCR3-CCR2-CCR5-CCRL2 group (with pairwise D9 0.47–
1, Figure S1). In the 3p22 block, low levels of LD were observed
between CCR8 and CX3CR1 SNPs (D9 ,0.40). The LD level
between 3p21 and 3p22 blocks is minimal.
Genetic associations with progression to AIDS
The identification of independent additional genetic factors in
this region, particularly for 3p21, is complicated by a moderate to
high level of LD (Figure S1). To detect genes or markers additional
to a primary predisposing variant(s) in a genetic region of high LD,
stratification analyses or using a restricted dataset are frequently
employed [45]. Stepwise regression is also a choice for assessing
the relative importance of different variants in the linked region
[46]. These approaches are feasible as the SNPs in this region have
a low to moderate correlation (for r
2, see Figure 2).
Effects of individual variants on AIDS progression
SNPs with allele frequencies of at least 5% were analyzed by
Kaplan-Meier survival curve analysis and Cox proportional
hazards model. We present the relative hazards (RH) of the
individual variants on survival to AIDS from analysis of 670 EA
seroconverters using multivariable Cox regression models in
Table 2. Four of the five SNPs in the 3p21 block revealed new
significant associations with delayed time progressing to AIDS,
after conditioning on HLA alleles and CCR5-D32 (Table 2).
Significant associations with differential progression to clinical
AIDS were observed for CCR3 -255C (RH=0.62, P=0.009,
Figure 2A), for CCRL2-243V (RH=0.66, P=0.03, Figure 2B),
and for CCRL2-167F (RH=1.89, P=0.0003, Figure 3A) and for
CCR8-27G (RH=1.44, P=0.004) (Table 2). Adjusting for
potential population stratification had little affect on the
significance of the associations (Table 2). Correcting for 7
chemokine receptor variants tested using a Bonferroni step-down
(Holm) correction [47], the associations for CCRL2-167Y, CCRL2-
243V, and CCR3-255C remained significant (P=0.002, 0.03, and
0.016, respectively), in addition to CCR5-D32 and CCR5-2459,
while CCR8-27G became non-significant (Table 2).
Effects of combined chemokine coreceptor variants on
AIDS progression
Using stepwise selection determined by the Akaike information
criteria (AIC), we built an optimal prediction model with the
genetic variants that were associated with AIDS progression in this
or previous studies (Table 3). From Table 3, we can see the
Table 1. Characteristics and allele frequencies of the chemokine receptor variants.
Gene Variant dbSNP ID Chromosome Position
1 Domain
2 EA freq.
3 AA freq.
3
CX3CR1 CX3CR1-V249I rs3732379 39282260 TM6 0.261 0.140
CX3CR1 CX3CR1-T280M rs3732378 39282166 TM7 0.159 0.040
CCR8 CCR8-A27G rs2853699 39348906 N-terminus 0.306 0.144
CXCR6 CXCR6-E3K rs2234355 45962984 N-terminus 0.006 0.438
CCR3 CCR3-255C (Y17Y)
4 rs4987053 46281704 N-terminus 0.083 0.103
CCR3 CCR3-P39L rs5742906 46281769 TM 1 0.004 0.013
CCR2 CCR2-V64I rs1799864 46374212 TM 1 0.1 0.15
CCR5 CCR5-2459A
5 rs1799987 46386939 promoter 0.56 0.42
CCR5 CCR5-D32 rs333 46389951 Intracellular 0.1 0.01
CCRL2 CCRL2-Y167F rs3204849 46425074 3rd ECL 0.394 0.134
CCRL2 CCRL2-I243V rs3204850 46425301 TM 6 0.085 0.016
1Chromosome position is based on the NCBI genome build 36.3;
2TM, Transmembrane domain; ECL, extracellular loop;
3Variant allele frequency (freq.) was obtained from participants in AIDS cohorts consisting of European American (EA) and African American (AA);
4Synonymous nucleotide T/C change at position 255 in the GenBank sequence U51241;
5Nucleotide G/A change at 2459 bp upstream of CCR5 ORF.
doi:10.1371/journal.pgen.1002328.t001
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Therefore, the best predictive model accounting for the rate of
progression to AIDS (1987 CDC definition) includes the newly
identified variants CCRL2-167F and -243V, CCR8-27G, as well as
previously known variants: the two locus CCR2-V64I-CCR5-D32
composite genotype, CCR5-2459, HLA class 1 homozygosity,
HLA-B*35Px, HLA-B*57 and HLA B*27 (without covariates,
AIC:1796.32, with 9 covariates, AIC:1737.28). The significance
level and RH values in this model represent that of each variant
after considering all other linked and unlinked variants (Table 3).
The rough shrinkage estimate is 0.88 (104/140), indicating that
the model is fairly reliable without further shrinkage or data
reduction treatment [48]. We calculated that R
2=0.11 for the
final fitted model, indicating that 11% of the variability in AIDS
progression can be explained with the variants in the model.
CCRL2- Y167F is associated with progression to AIDS
The strongest new association was for CCRL2-Y167F with
progression to clinical AIDS. The common 167F allele (allele
frequency 67% in EA) had a significant dominant detrimental
effect on progression to AIDS-defining conditions (CDC 1987 case
definition) (RH=1.89, P=0.0003, Wald test; P=0.0001, Likeli-
hood ratio test; n=670 seroconverters) in the Cox proportional
hazards model (Table 2 and Table 3, Figure 3A). When the
analysis was restricted to individuals not carrying CCR5-D32
(n=539), the association of CCRL2-167F with AIDS remained
significant (RH=1.69, 95% CI 1.20–2.38), indicating that the
CCRL2-167F association is independent of CCR5-D32 and not due
to its linkage disequilibrium with the latter.
CCRL2- Y167F and pneumocystis pneumonia (PCP)
In an explanatory analysis, we tested whether CCRL2- Y167F
affects AIDS progression through a specific AIDS-defining illness. A
Cox model analysis in the seroconverter group showed significantly
faster progression to PCP for carriers of 167F (RH=2.84, 95% CI
1.28–6.31, P=0.007; Figure 3B), but no differential effect on
Kaposi’s sarcoma, microbacterial avium infection, cytomegalovirus,
or lymphoma (P.0.05, data not shown).
Figure 2. Genetic effect of CCR3-255C and CCRL2-243V on AIDS progression. Kaplan-Meier survival curves of time progression since HIV-1
infection to AIDS (1987 CDC definition) were plotted for genotypes of CCR3-255C (A) and CCRL2-243V (B). Circles on the curves indicate those
censored.
doi:10.1371/journal.pgen.1002328.g002
Table 2. Effects of chemokine receptor variants on AIDS progression.
Adjusted by HLA alleles
1 Adjusted for population stratification
2
Variant Model RH 95% CI praw RH 95% CI Peigen PHolm
3
CCR3-255C dom 0.62 0.43–0.89 0.009 0.59 0.40–0.85 0.004 0.016
CCR2-64I dom 0.78 0.58–1.05 0.10 0.79 0.57–1.09 0.14 0.14
CCR5- 2459A rec
4 1.51 1.18–1.93 0.001 1.66 1.27–2.15 0.0002 0.001
CCR5-D32
5 dom 0.63 0.46–0.86 0.003 0.58 0.42–0.80 0.0008 0.004
CCRL2-F167 dom 1.89 1.34–2.66 0.0003 1.90 1.33–2.71 0.0004 0.002
CCRL2-243V dom 0.66 0.46–0.96 0.03 0.60 0.40–0.89 0.01 0.03
CCR8-27G dom 1.44 1.13–1.85 0.004 1.34 1.03–1.73 0.028 0.056
1The rate of progression to AIDS (1987 CDC definition [66]) were calculated with the Cox proportional hazards model. The analyses were adjusted for age, sex and
covariates CCR5-D32, and four HLA alleles (Class I homozygosity, B27, B35Px and B57). CI (confidence interval), RH (relative hazard);
2After including eigenvector values for the top two principle components as a covariate in the Cox regression analysis to control for potential population stratification.
Eigenvector values were obtained from Eigensoft program by performing a principal component analysis of 700,022 SNPs in the previous GWAS study [71];
3The adjusted p-values further correcting for multiple testing of 7 chemokine receptor variants using the Holm’s step-down Bonferroni method;
4CCR5-2459A (rs1799987, Tag SNP of CCR5-P1, previously shown to be associated with AIDS in a recessive model [15];
5With adjustment of CCR5-2459A.
doi:10.1371/journal.pgen.1002328.t002
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due to LD (D9=0.76, r
2=0.47) with CCR5-2459 that associated
with AIDS progression [16], we restricted the analysis in a group
of SC (n=365) that do not carry the homozygous CCR5-2459
genotype; the CCRL2-167F association with PCP remained
significant (OR=2.42, 95% CI 1.09–5.36), in support of its
independent role.
Possible function of CCRL2 F167Y
Evolutionary conservation of CCRL2. We assessed the
homology of CCRL2 with other C-C chemokine receptor family
genes. CCRL2 shares over 40% sequence homology with known
chemokine receptors such as CCR1, -2, -3 and -5 but lacks the
DRYLAIV motif in the second extracellular loop that is usually
required forthe signaling capacityofchemokinereceptors[49]. The
alignment of mammalian CC chemokine coreceptor sequences
shows that the 167 site and surrounding region are highly conserved
(Figure S2). Phenylalanine (F) at position 167 is apparently ancestral
as it occurs in chimpanzee and macaque. Phenylalanine (F) or other
nonpolar amino acids occur at the position homologous to human
CCRL2-167 in 78 of the 82 chemokine receptors, including all
receptorsknown to be functional, whilea polaramino acid occurs at
this position in two cases for the non-signaling FY DARC receptor.
Tyrosine (Y) never occurs at this position except for human CCRL2.
Table 3. Sequential stepwise regression for Cox PH model selection and maximum likelihood estimates of genetic covariates
associated with AIDS progression.
Variable AIC with Covariates
1 The final model with 9 covariates
3 (AIC=1737.28)
Estimate/S.E. RH (95% CI) P
1 HLA B35 px dom 1783.70 0.86/0.0.23 2.37(1.52–3.69) 0.0001
2 HLA B27 dom 1770.23 21.06/0.31 0.35(0.19–0.64) 0.0007
3 HLA homozygosity 1766.52 0.31/0.12 1.36 (1.08–1.71) 0.009
4 CCRL2-243V dom 1761.29 20.64/0.24 0.53 (0.33–0.84) 0.007
5 CCRL2-167F dom 1753.95 0.66/0.23 1.93 (1.23–3.01) 0.004
6 CCR5-D32 or CCR2-64I 1747.70 20.54/0.17 0.58 (0.42–0.82) 0.002
7 CCR8-27G dom 1742.41 0.43/0.15 1.53 (1.15–2.04) 0.004
8 B57 dom 1737.32 20.80/0.37 0.45 (0.22–0.92) 0.028
9 CCR5-2459A rec 1737.28
2 0.26/0.18 1.30 (0.91–1.87) 0.15
10 CCR3-255C dom 1738.21
NOTE. AIC, Akaike information criteria; S.E., standard error; RH, relative hazard; CI, confidence interval; dom, dominant genetic model; rec, recessive model.
1AIC without covariates (null model)=1796.32;
2The best model with minimal AIC is achieved at the ninth step including first 9 covariates entered.
3The X
2 value for likelihood ratio test, degree of freedom, 9; P=6.24610
213; and shrinkage of the model=(77.0429)/77.04=0.88. All analyses were stratified with age
groups that known to modify AIDS progression.
doi:10.1371/journal.pgen.1002328.t003
Figure 3. Genetic effect of CCRL2-167F on AIDS progression and PCP. Kaplan-Meier survival curves of time progression since HIV-1 infection
to AIDS (1987 CDC definition) (A) or to PCP (B) were plotted for CCRL2-Y167F genotypes. Circles on the curves indicate those censored.
doi:10.1371/journal.pgen.1002328.g003
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functional consequence.
Impact of F167Y on CCRL2 topology. The impact of
F167Y on CCRL2 transmembrane (TM) topology was assessed
using ConPred II, [50]. 167F is located in the third extracellular
loop adjacent to the 4
th TM domain. The F to Y substitution
introduces a hydrophilic residue that changes the boundary of the
TM domain and the conformation of the nearby domains: TM
domains 3, 4 and 5 were formed by residues 104–124, 146–166
and 201–221 with CCRL2 carrying 167F, but were formed by
residues 103–123, 145–165 and 202–222 with CCRL2-167Y,
respectively (Figure S3).
Three-dimensional protein structure prediction. The
effect of the Y167F amino acid substitution on the structure of
the CCRL2 receptor was predicted by PROTINFO program. In
the structure incorporating 167Y, the hydroxyl (OH) group of the
tyrosine makes a hydrogen bond with the nitrogen atom of glycine
108 (G108) (Figure S4). This hydrogen bond is not present with
F167, or with the other amino acids commonly observed at this
position.
Surrogate migration assay using CCR3. As an indirect
test of possible function of CCRL2-F167Y, HEK293 cells
expressing human CCR3 containing either phenylalanine (
169F)
or tyrosine (
169Y) at the homologous position were tested for
migration in a chemotaxis assay. Mutation of
169Ft o
169Yi n
CCR3 markedly reduced (3-fold) the migration of HEK293 cells
in response to eotaxin (Figure S5), indicating a role of
169Fi n
CCR3 function and by analogy suggesting that CCRL2-F167 may
be a functionally superior receptor than CCRL2-167Y.
Chemotaxis of CCRL2. We tested chemotactic responses of
HEK293 cells transfected with either CCRL2-F167 or CCRL2-
167Y. We observed no chemotactic responses to a panel of 13
chemokines or peptides including the HIV-1 inhibitory
chemokines CCRL3, 4, 5 and CXCL12, suggesting CCRL2 is
not a receptor of these chemokines. However, our experiments did
not include the recently identified CCRL2 ligands, chemerin and
CCL19 [51,52], due to availability.
Discussion
We investigated the impact of genetic variation of 3p21–22
chemokine receptor genes on HIV/AIDS in this population-based
association study. We identified a total of 6 exonic variants in
CCR3, CCR8, CXCR6 and CCRL2 in 144 samples with extreme
phenotypes. Through Cox regression survival analysis of the
variants in HIV-1 natural cohorts, we identified three polymor-
phisms (CCRL2-Y167F, CCR3-255C and CCR8-27G) as having
previously unidentified correlation with AIDS progression that
appear to confer additional effect beyond the well-studied AIDS-
modifying polymorphisms CCR5-D32, CCR5-P1/CCR5-2459A,
and CCR2-64I. CCRL2-167F was associated with strong acceler-
ated progression to AIDS, resulted almost entirely from rapid
development of the AIDS-defining disease PCP.
The coverage of SNPs in the 3p21–22 region is limited in the
GWAS SNP chips. Several exonic SNPs (CCRL2-167F, -243V,
CCR8-27G, CCR5-2459A, CCR5- D32) genotyped in this study
were not included in the SNP chips that have been used in GWAS
for HIV-1 [3,5–8], highlighting the ongoing need of candidate
gene analysis in the GWAS era. The newly observed effects of
chemokine coreceptor genes thus await further replication.
It must be cautioned that the combination of the presence of
multiple AIDS associations in this chemokine receptor complex,
and the LD between the receptor genes, makes determining the
true source of the associations difficult. Overall, however, the
association analysis points to receptor gene variant associations
beyond those that can be attributed to the known AIDS affecting
receptor gene polymorphisms. The association of additional
chemokine receptors, beyond the primary CCR5 and CXCR4,
with AIDS progression is plausible as several of these have been
shown to bind to HIV in varying degrees [26,35,36,39–42,53].
The complexity of associations in this region makes it essential to
identify a functional effect of the genetic variants on disease, before
concluding that the associations are real. It should be noted that
we may have not detected all existing SNPs in the region and was
also underpowered in detecting rare SNPs (1%). We found that
another CCRL2 exonic SNP in the public domain (168M,
rs6441977) was not associated with progression to AIDS-87
(RH=0.84, 95% 0.50–1.39) in our seroconverters. We performed
haplotype analysis for the three exonic SNPs in CCRL2 and found
that only the haplotypes bearing rs3204849 A (CCRL2 Y167F) and
rs3204850 (V243I) were associated with AIDS; the haplotype
bearing rs6441977A (V168M) had no effect. No additional
information was gained by performing a haplotype analysis
compared to single SNP analysis.
With these caveats we argue that the association of the CCRL2-
167F variant is worthy of interest. First, within the noted limits of the
association analysis, the association is quite strong (RH=1.9,
P=0.002, corrected), remains significant with CCR5-D32 taken into
account,andinanautomaticselectionanalysiswithallknownfactors
taken into account. Second, although there is no direct demonstra-
tion of function for this polymorphism, and the F to Y substitution is
generally a conservative one, several lines of phylogenetic, chemical
modeling, and indirectexperimentaldata suggestthat CCRL2-167Y
significantly alters the properties of this receptor.
Protein structure modeling data suggest that the risk-associated
F to Y substitution could change the boundary of the
transmembrane domain, and introduce a hydrogen bond. Of
particular interest is the alignment data of the conservation of this
residue among CC chemokine receptors. Strikingly, phenylala-
nine, the ancestral alternate variant to the AIDS risk tyrosine
variant, or another nonpolar amino acid, occurs at this position in
all receptors known to be functional [54]; a polar amino acid only
occurs in the two cases of the nonsignaling DARC receptor.
Further, substitution of tyrosine for phenylalanine at this position
in the functional receptor CCR3 reduced migration of HEK293
cells in response to eotaxin threefold. We emphasize that all of
these tests are in silico or indirect, and direct test of the effect of the
F to Y substitution on the function of CCRL2 remains to be done;
new knowledge of the functions and ligands of CCRL2 should
make this more straightforward.
The association of CCRL2 with AIDS and PCP is unique as
CCRL2 has not been shown to serve as a coreceptor for HIV-1.
Our chemotaxis assay experiments excluded 11 common chemo-
kines as ligands of CCRL2. The association does not appear to be
a general function of increased HIV susceptibility, but instead
specifically attributable to an increase in PCP among individuals
carrying this receptor variant. PCP, caused by Pneumocystis jirovecii,
is the most common opportunistic infection in untreated HIV-1-
infected immunosuppressed persons. PCP is mediated by marked
inflammatory responses in lung involving macrophages and
chemokines and cytokines [55]. The association of CCL2 with
PCP might be attributable to two aspects of CCRL2: immune
regulation or direct interaction with HIV. CCRL2 may affect PCP
through its immune regulating role at local inflammation sites,
possibly by concentrating and presenting chemokines [51,52,56].
CCRL2 was rapidly upregulated in murine lung macrophages
following inflammation induction [57] and deficiency of CCRL2
impaired lung dendritic cell migration [58]. Alternatively, CCRL2
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sequestering with CCL5 or anti-HIV chemokines [56], or may
serve as a coreceptor for some strains of HIV-1. The mechanism of
CCRL2-F167Y effect on PCP remains to be explored.
In summary, this comprehensive study of the chromosome 3
chemokine receptor cluster region identified multiple genetic
variants that associated with HIV disease. The strongest new
association appears to result from an increased susceptibility to
PCP, rather than from a specific effect on HIV. Added to the
existing knowledge of the effect of the chromosome 3 chemokine
receptors on HIV disease, which has been already been exploited
therapeutically, our results affirm this gene complex as a fertile
ground for further research, both for HIV and potentially for a
broad range of additional diseases.
Materials and Methods
Ethics statement
Institutional review boards (IRB) at National Cancer Institute,
National Institutes of Health and participating institutes approved
the study protocols. Written informed consent was obtained from
all study participants and/or their legal guardians.
Study participants
The study group includes 674 HIV-1 seroconverter European
Americans, 669 seronegatives enrolled in the following natural
history HIV-1 cohort studies: Multicenter AIDS Cohort Study
(MACS) [59], the San Francisco City Clinic Cohort Study
(SFCCC) [60], AIDS Link to the Intravenous Experience (ALIVE)
[61], Hemophilia Growth and Development Study (HGDS) [62],
and the Multicenter Hemophilia Cohort Study (MHCS) [63].
Seroconversion date was estimated as the midpoint between the
last seronegative and the first seropositive HIV-1 antibody test
date (mean interval 0.79 years, range 0.07–3.0 years). The
censoring date was the earliest of the date of the last recorded
visit, or July 31, 1997 for the ALIVE cohort, or December 31,
1995 for all other cohorts, to avoid the confounding effect of highly
active anti-retroviral therapy (HAART). A later censoring date
was used for ALIVE cohort because few ALIVE participants
received HAART prior to July 31, 1997 [64].
Resequencing and SNP identification
A panel of 72 EA and 72 AA samples representing extreme
phenotypes for infection and progression (rapid progression, long
term non-progression, and infection resistance) were used for SNP
identification. The 59 and 39 untranslated (UTR) and coding
regions of the CCR3, CCR8, CCRL2, and CXCR6 genes were PCR
amplified by overlapping primer sets (Table S2). PCR products
were resequenced by BigDye terminator (Applied Biosystems,
Foster City, CA). We did not sequence or genotyping SNPs in
CCR1, CCXCR1, CCR9 and CCR4 as they are not recognized as
HIV-1 coreceptors [26,33–36] (reviewed by [11,37]).
Genotyping of genetic variants
Genotyping was done using PCR-restriction fragment length
polymorphism (RFLP) or TaqMan assays. PCR primer sequences,
TaqMan probes and primers, PCR conditions, and restriction
enzymes used to genotype each variant are listed in Table S1.
Briefly, PCR was carried out with 35 cycles of denaturing at 94uC
for 30 s, annealing at 54–60uC for 30 s and extension at 72uC for
45 s. TaqMan assays were performed according to the manufac-
turer’s manual (Applied Biosystems, Foster City, CA). The
CX3CR1 variants V249I and T280M were typed as previously
reported [65].
Statistical analysis
Kaplan-Meier survival statistics and the Cox proportional
hazards (PH) model (Cox PH model) were used to assess the effects
of genetic variants on the time of progression from HIV-1 infection
to AIDS (1987 CDC definition) [66], using PROC PHREG and
LIFETEST of SAS version 9.13 (SAS, Cary, North Carolina). For
SNPs that showed significant association with AIDS development,
explanatoryanalyseswere performed fortheirspecificimpactonthe
AIDS-defining diseases Pneumocystis pneumonia (PCP), Kaposi’s
sarcoma, microbacterial avium infection, and cytomegalovirus. The
relative hazard (RH) and significance of associations were
determined using a Cox PH model without or with adjustment
for confounding genetic factors not on chromosome 3: for EA HLA-
B*27 and HLA-B*57, HLA-B*35Px,a n dHLA Class I homozygosity
[1,67,68]; for AA CCRL5-In1.1, HLA-B*57 and HLA Class I
homozygosity [1,19,67]. CCR2-64I, CCR5-D32 and CCR5-2459
were also included as covariates in the adjusted multivariable
regression analysis. CCR5 promoter haplotypes (P1, P2, and P4) are
tagged by SNPs CCR5-2459 (rs1799987) and rs2734648 [43]. A
visual inspection of the data with Kaplan-Meier survival curves was
performed to determine the genetic models to be used in the Cox
PH regression model. A dominant genetic model was tested for all
genetic factors in this study, except for CCR5-2459 (recessive)
[15,16]. Participants were stratified by sex and by age at
seroconversion: 0–20, .20–40, and over 40 years.
To determine the best explanatory set of genetic variants, while
minimizing the number of comparisons in model selection, We
used StepAIC procedure to build Cox proportional hazards
models for the AIDS-1987 phenotype based on stepwise
regression, Akaike information criteria (AIC), and the best subset
selection [69]. Here we used PROC PHREG in SAS software with
SLENTRY=0.99 and SLSTAY=0.995 (values chosen close to 1
to generate a sequence of models from null models to full model
ordered by AIC) [48]. Model uncertainty caused by including
large number of variables can be estimated by shrinkage (LR-p)/
LR, where LR denotes the likelihood ratio x
2 and p denotes the
number of the predictors in the final model. A shrinkage below
0.85 raises concern of overfitting [48]. It is recommended that no
more than m (the number of uncensored event)/10 predictor
degree of freedom p (number of parameters) should be examined
to fit a multiple regression model. As in our sample, there were 194
events without censoring, we expect that fitting with ,19 variables
would be appropriate [48].
To control for potential population stratification, we adjusted
the regression analysis with eigenvector values [70]. Eigenvector
values were obtained by performing principal component analysis
of 700,022 SNPs from a previous GWAS study carried out in the
same samples [71]. In the Cox regression analysis, eigenvector
values for the top two principle components were included as
covariates. The genomic inflation factor in this seroconverter
population showed minimal systematic overall bias due to
population structure in regards to disease progression phenotype
as it was quite close to 1.0 (l=1.01) (expected under no
population stratification) [71].
We further corrected for multiple comparisons by counting 7
chemokine receptor variants tested using a Bonferroni step-down
(Holm) correction method [47], as implemented in the MUL-
TITEST procedure in SAS.
The ‘‘generalized’’ R
2 statistic in Cox model is based on the
likelihood-ratio statistic (LRT) for testing the global null hypothesis
[72]. The formula is given as: R
2=12e
2(LRT/n), where
LRT=22logL(0)2[22logL(p)], n is the total sample size, logL(0)
is the log-likelihood for a null model with no covariates, and
logL(p) is the log-likelihood for the fitted model with p covariates.
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absolute unsigned value of Lewontin’s D9 statistic [73]. P values
represent significance of departure from the null hypothesis that
the pair is in equilibrium. All P values are two-tailed. Haploview
was used for the LD plots.
Prediction of CCRL2 protein structures
Three-dimensional models of the two CCRL2 proteins with
167F or 167Y were constructed using the PROTINFO structure
prediction server (http://www.protinfo.compbio.washington.edu),
using the comparative modeling protocol [74,75]. The detailed
modeling method is presented in Text S1. The CCRL2 TM
topology was established using ConPred II (http://bioinfo.si.
hirosaki-u.ac.jp/,ConPred2/), a predication program based on
consensus results of several prediction methods including TMpred,
TMAP,TMHMM, HMTOP and MEMSAT [50].
Expression of human CCRL2 in HEK293 cells
cDNAs coding for the full-length open reading frame (ORF) of
human CCRL2 carrying 167Y or 167F were PCR amplified from
two individuals with the respective homozygous genotype with
proofreading DNA polymerase pfu (Stratage, La Jolla, CA). After
confirmation of sequence accuracy, they were ligated into the
pcDNA3 (Invitrogen, Gaithersburg, MD). Human embryonic
epithelial cells line HEK293 was transfected with the constructs of
CCRL2-167F or CCRL2-167Y. Stable transfectants were selected
by culturing the cells in 800 mg/ml G418. Once the stable cell
lines were established, they were examined for chemotactic
responses to chemokines.
Chemotaxis assays
Migration of CCRL2-167F and CCRL2-167Y transfected
HEK293 cells was assessed using a 48-well microchemotaxis
chamber technique. They were examined for chemotactic
responses to the following chemokines: CCL5, CCL3, CCL4,
CCL2, CCL8, CCL7, CCL11, CXCL12, CCL21, CCL20, and
CXCL10. The cells were also tested for migration in response to
chemotactic peptides using formayl peptide receptors, including W
peptide and MMK-1 (Text S1).
Expression of human CCR3 in HEK293 cells
A cDNA coding for
169Y-CCR3 was created from the wild-type
human
169F-CCR3 ligated into the pcDNA3, which were used to
transfect HEK293 cells (Text S1).
Supporting Information
Figure S1 Linkage disequilibrium of variants in 3p21 chemokine
receptor genes. LD was shown for D9 and r
2 in European Americans.
(TIF)
Figure S2 Alignment of a segment of sequences corresponding
to the CCRL2-F167Y residue from chemokine receptor genes.
(TIF)
Figure S3 Predicted CCRL2 transmembrane topology change
by F167Y change.
(TIF)
Figure S4 Three-dimensional models of the 167Y (top) and
F167 (bottom) CCRL2 proteins. The models are shown with
virtual bonds connecting the CA atoms. The atoms in residue 167
are shown in spacefill view, with the carbons in white, oxygens in
red and nitrogens in blue. The hydroxyl (OH) group of 167Y
forms a hydrogen bond with the nitrogen atom of glycine 108,
which is not present in the F167 allele.
(TIF)
Figure S5 Migration of HEK293 cells expressing wild-type
(
169F) or mutated (
169Y) CCR3 in response to eotaxin. A. Surface
expression of CCR3 on each cell line was evaluated by flow
cytometry with anti-CCR3 mouse monoclonal Ab. B. Migration of
each cell line in response to 1, 10 or 100 ng/ml of eotaxin was
evaluated and presented as chemotactic index (CI).
(TIF)
Table S1 Genotyping primers, PCR conditions, and Restriction
Enzymes.
(DOC)
Table S2 Primer sequences for PCR amplification and direct
sequencing.
(DOCX)
Text S1 Supplementary methods.
(DOC)
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